Indoco Remedies zooms on getting USFDA’s nod for Apixaban Tablets

14 Sep 2020 Evaluate

Indoco Remedies is currently trading at Rs. 232.00, up by 10.80 points or 4.88% from its previous closing of Rs. 221.20 on the BSE.

The scrip opened at Rs. 220.70 and has touched a high and low of Rs. 234.00 and Rs. 220.70 respectively. So far 12494 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 285.00 on 13-Apr-2020 and a 52 week low of Rs. 133.10 on 11-Oct-2019.

Last one week high and low of the scrip stood at Rs. 237.10 and Rs. 213.60 respectively. The current market cap of the company is Rs. 2109.32 crore.

The promoters holding in the company stood at 58.69%, while Institutions and Non-Institutions held 16.54% and 24.77% respectively.

Indoco Remedies has received approval from US Food and Drug Administration (USFDA) for its ANDA for Apixaban Tablets 2.5mg & 5mg. The products are therapeutically equivalent to the Reference Listed Drug ‘Eliquis’ of Bristol-Myers Squibb (BMS). Apixaban is an anticoagulant, or blood thinner. It is used for patients with health problems caused by a blood clot. The US market size of Apixaban Tablets is $11,037 million as per IMS MAT June 2020 data.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Indoco Remedies Share Price

240.65 -11.10 (-4.41%)
09-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1776.20
Dr. Reddys Lab 1246.25
Cipla 1490.70
Zydus Lifesciences 919.90
Lupin 2052.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×